Company Filing History:
Years Active: 2021-2025
Title: Innovations of Uyanga Tsedev
Introduction
Uyanga Tsedev is a notable inventor based in Somerville, MA (US). He has made significant contributions to the field of gene therapy, holding a total of 4 patents. His work focuses on innovative methods for delivering therapeutic genes using engineered phage-derived particles.
Latest Patents
One of his latest patents is the M13 phage-based gene therapy platform. This invention involves an engineered phage-derived particle (PDP) designed for expressing a transgene in target cells transduced with a bacteriophage. The PDP includes several key components: less than about 500 bp of DNA from the bacteriophage genome, an ITR-flanked therapeutic gene up to 20 kb, an endosomal escape sequence, a nuclear localization sequence, and a cell-specific targeting moiety. This innovative design allows the PDP to escape lysosomal degradation, traffic across the nuclear envelope, and express a therapeutic gene in mammalian cells. Another significant patent focuses on the optimization of circular single-stranded DNA using M13 phage. This patent provides methods and compositions for producing single-stranded DNA (ssDNA) with uniform length.
Career Highlights
Uyanga Tsedev is affiliated with the Massachusetts Institute of Technology, where he continues to advance his research in gene therapy. His work has garnered attention for its potential applications in treating various genetic disorders.
Collaborations
He has collaborated with notable colleagues, including Angela M. Belcher and Fred Lam, contributing to a dynamic research environment that fosters innovation.
Conclusion
Uyanga Tsedev's contributions to gene therapy through his patents and research at the Massachusetts Institute of Technology highlight his role as a leading inventor in the field. His innovative approaches have the potential to significantly impact medical science and therapeutic applications.